
Tansna Therapeutics Inc Profile last edited on: 9/8/2014
CAGE: 65SY8
UEI: PLK6CFD4TF25
Business Identifier: Oral Medication to treat Epilepsy Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
Location Information
Location: Single
Congr. District: 01
County: St. Louis city
Congr. District: 01
County: St. Louis city
Public Profile
Tansna Therapeutics, Inc., is a drug discovery and development company focused on novel therapies for the treatment of CNS disorders, with an initial focus on epilepsy. The company has identified a library of proprietary compounds that are derivatives of the marketed anesthetic propofol. These compounds are drug-like small-molecules, exhibit broad-spectrum CNS pharmacology, and are non-sedating. Tansnas lead is a novel anticonvulsant for the treatment of epilepsy - a debilitating condition and one of the most common neurological disorders with at least 50 million people affected worldwide. Chronic, daily treatment with anticonvulsant drugs continues to be the standard of care for these patients, who often require several drugs and endure severe side effects (including headache, fatigue, and cognitive impairment) in an attempt to manage their seizures. Despite these efforts, a staggering 30% of epilepsy patients are refractory, which means that they are unable to achieve adequate seizure control using existing medications. Thus, there remains a significant unmet need for more effective and safer anticonvulsant drugs. Tansna aims to develop an oral anticonvulsant agent with an acceptable safety profile that will effectively reduce seizure frequency in all epilepsy patients, particularly those with refractory epilepsy. Previously located in Iowa, in 2013 Tansna relocated to St Louis due to the avaliablity investment funding from Missouri based organizations.
Extent of SBIR involvement
Synopsis: Awardee Business Condition
Employee Range
5-9Revenue Range
.5M-1MVC funded?
YesPublic/Private
Privately HeldStock Info
----IP Holdings
1-4Awards Distribution by Agency
Most Recent SBIR Projects
Year | Phase | Agency | Total Amount | |
---|---|---|---|---|
2011 | 1 | NIH | $181,299 | |
Project Title: Design and Synthesis of Novel Anticonvulsant Molecules. |
Key People / Management
Robert Karr -- President and Chief Executive Officer
Kathleen Larrimer Beckmann -- Chief Financial Officer:
George H Capps -- Director Of Business Development
Alan Macinnes -- Vice President, Research And Development
Rajesh Kumar Mishra
Kathleen Larrimer Beckmann -- Chief Financial Officer:
George H Capps -- Director Of Business Development
Alan Macinnes -- Vice President, Research And Development
Rajesh Kumar Mishra